Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

H1N1 seasonal influenza virus vaccine - Vaxart

Drug Profile

H1N1 seasonal influenza virus vaccine - Vaxart

Alternative Names: Ad-HA-dsRNA; Seasonal influenza vaccine - Vaxart; VXA-A1.1

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaxart
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H1N1 subtype

Most Recent Events

  • 06 Oct 2018 Immunogenicity data from a phase II trial in Influenza-A virus H1N1 subtype prevention presented at the ID week (IDW-2018)
  • 03 Apr 2018 Vaxart completes a phase I trial for Influenza-A virus H1N1 subtype in USA (NCT03121339)
  • 31 Jan 2018 Efficacy data from a phase II trial in Influenza-A virus H1N1 subtype released by Vaxart
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top